Sur Bogota, Colombia
- Featured
TemPo Studies
**All eligible study participants will receive at no cost:** • Study-related consultation and care • Study visits, tests, assessments, and procedures • Study drugs (investigational drug or placebo)
Phase
N/ASpan
212 weeksSponsor
Cerevel TherapeuticsAdventura, Florida
Recruiting
- Featured
A Phase III, Randomized, Double-blind, Placebo-controlled Study of Subcutaneous Secukinumab in Autoinjectors, to Demonstrate Efficacy at 24 Weeks and Long Term Safety and Efficacy up to 3.5 Years in Subjects With Active Psoriatic Arthritis
The purpose of this study is to provide 24 - 52 week efficacy, safety and tolerability data, as well as up to 3.5-year efficacy, safety and tolerability data in subjects with active Psoriatic Arthritis despite current or previous nonsteroidal anti-inflammatory drug (NSAID), disease-modifying antirheumatic drug (DMARD) therapy and/or previous anti-tumor necrosis factor alpha (TNFa) therapy. Novartis Pharmaceuticals 1-888-669-6682 ClinicalTrials.gov identifier: NCT01989468
Phase
3Span
Sponsor
NovartisAventura, Florida
Recruiting
- Featured
The INSYTE (Management of Parkinson's Disease Psychosis in Actual Practice) Study
Phase
N/ASpan
Sponsor
ACADIA Pharmaceuticals Inc.Aventura, Florida
Recruiting
- Featured
PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase Inhibition Using K0706
This study is designed to assess the ability of K0706 to slow the progression of PD. Preclinical animal model data have already demonstrated that K0706 has neuroprotective activity, but further development will require human clinical experience. This study will also allow determination of safety and tolerability of K0706 over many months in subjects with PD.
Phase
2Span
246 weeksSponsor
Sun Pharma Advanced Research Company LimitedAventura, Florida
Recruiting
- Featured
The Alzheimer's Network for Treatment and Diagnostics (ALZ-NET)
ALZ-NET collects data from individuals who are being evaluated for treatment or those receiving novel (since 2021) FDA-approved therapies for Alzheimer’s disease. ALZ-NET will track clinical, safety and long-term health outcomes of individuals in real-world settings from a variety of backgrounds and communities. This network is sponsored by the Alzheimer’s Association and managed by the American College of Radiology. Why join ALZ-NET? This is a voluntary health care provider-enrolled patient network, but with patients’ willingness to provide data on their Alzheimer's treatment and care, ALZ-NET researchers can learn about real world patterns in diagnosing and treating Alzheimer’s disease. By understanding patterns in care today, ALZ-NET can help health practitioners treat Alzheimer’s disease now and in the future. ALZ-NET aims to be a resource for evidence gathering, information sharing, and education across clinical and research communities to support and improve care of individuals living with Alzheimer’s disease. What is expected by participating in ALZ-NET? ALZ-NET does not require any additional procedures to be completed outside of the care a patient should otherwise be receiving. Participants will visit their care provider as they normally would without participating in ALZ-NET. ALZ-NET provides resources and recommendations for best practices that your provider may choose to implement in your care plan. Once registered, participation in ALZ-NET continues for as long as consent is provided and care is being received by the care provider. All care that is provided will be charged to the patient’s health insurance provider. Standard co-payments will remain the patient’s responsibility, as they would without participating in ALZ-NET. How can I participate? ALZ-NET does not require any additional effort on a participant’s behalf other than routinely visiting your health practitioner. Your health practitioner will advise if you are eligible to participate in ALZ-NET. Your health practitioner needs to be located at an active enrolled ALZ-NET site. If your provider is not actively participating in ALZ-NET, you can search our directory for a provider that is participating as ALZ-NET continues to expand to sites across the country. How to find a site To FIND A PARTICIPATING HEALTH PRACTITIONER Go to “Find a Site” at alz- net.org[ https://www.alz-net.org/Find-a-Site](https://www.alz-net.org/Find-a- Site) Search for a health practitioner who is participating in ALZ-NET in your state or near your ZIP code. If you need further assistance locating a participating site near you, please call 866-507-7254
Phase
N/ASpan
Sponsor
Alzheimer's AssociationAventura, Florida
Recruiting
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
Phase
3Span
251 weeksSponsor
Madrigal Pharmaceuticals, Inc.Hallandale Beach, Florida
Recruiting
Hallandale Beach, Florida
Recruiting
Lu AF28996 in Participants With Parkinson's Disease (PD)
The study consists of different parts. Part A of the study will consist of once daily (OD) cohorts (OD Cohort 1 to 3), as well as twice daily (BID) cohorts (BID Cohorts A1 and A2). Part B will consist of 3 cohorts (Cohorts B1, B2, and B3) whereby participants will be administered Lu AF28996 BID.
Phase
1Span
310 weeksSponsor
H. Lundbeck A/SHallandale Beach, Florida
Recruiting
Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease
The study will be conducted in three periods: - Screening Period (up to 4 weeks) during which patient eligibility will be assessed; - Double-blind Treatment Period (4 weeks) in which all patients will be randomized to receive placebo or Lenrispodun 30 mg/day in 1:1 ratio. - Safety Follow-up Period (1 week) in which all patients will return to the clinic for a safety follow-up visit approximately one week after the last dose of study treatment.
Phase
2Span
138 weeksSponsor
Intra-Cellular Therapies, Inc.Hallandale Beach, Florida
Recruiting
A Clinical Study of Enlicitide in Participants With Severe Renal Impairment (MK-0616-032)
Phase
1Span
26 weeksSponsor
Merck Sharp & Dohme LLCHallandale Beach, Florida
Recruiting
Healthy Volunteers